title: Hydroxycarbamide: clinical aspects.
abstract: Due to its oral route of administration and mild toxicity profile, as well as its potent laboratory and clinical effects, hydroxyurea (or hydroxycarbamide) has been the primary focus of fetal hemoglobin (HbF) induction strategies for the treatment of children with sickle cell anemia (SCA). When administered orally once a day, hydroxyurea treatment is very well tolerated with little short-term toxicity. Hydroxyurea has documented laboratory efficacy with increases in Hb and HbF; treatment also significantly reduces the number of painful episodes, acute chest syndrome, transfusions, and hospitalizations. Most young patients reach a maximum tolerated dose of hydroxyurea at 25-30 mg/kg/d, where they will achieve key laboratory thresholds (Hb ≥ 9 g/dL and HbF ≥ 20%) without excessive myelosuppression. Potential long-term toxicities continue to be of great concern and should be monitored in all patients with SCA who receive hydroxyurea therapy. To date, however, no increases in stroke, myelodysplasia, or carcinogenicity have been detected in SCA patient cohorts, with drug exposure now reaching 15 years for some treated children. Taken together, available evidence suggests that hydroxyurea represents an inexpensive and effective treatment option that should be offered to most, if not all, patients with SCA. As countries in Africa develop newborn screening programs to identify SCA, the widespread use of hydroxyurea may prove to be a useful treatment to help ameliorate the disease in resource-limited settings. Hydroxyurea is the only currently available disease-modifying therapy for SCA, and is emerging as a safe and effective treatment for all patients with SCA, in both developed and developing countries.
authors: Center for Global Health, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street, Houston, TX 77030, USA. reware@bcm.edu
authors: Russell E
authors: RE
authors: Ware
mesh_terms: D000380:Agranulocytosis / Q000139:chemically induced; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000986:Antisickling Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003906:Developing Countries; D005544:Forecasting; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017495:Hyperpigmentation / Q000139:chemically induced; D020714:Maximum Tolerated Dose; D015337:Multicenter Studies as Topic; D016896:Treatment Outcome
chemical_list: D000986:Antisickling Agents; D006918:Hydroxyurea
references: Arch Pediatr Adolesc Med. 1994 Aug;148(8):796-804
references: 7519102
references: Hematology Am Soc Hematol Educ Program. 2009;:62-9
references: 20008183
references: J Pediatr. 2001 Dec;139(6):790-6
references: 11743503
references: Am J Dis Child. 1993 Nov;147(11):1197-202
references: 8237915
references: Blood. 2012 Apr 26;119(17):3925-32
references: 22318199
references: J Natl Med Assoc. 2009 Oct;101(10):1046-51
references: 19860305
references: Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11869-74
references: 18667698
references: Pediatr Clin North Am. 2008 Apr;55(2):483-501, x
references: 18381097
references: J Clin Invest. 1984 Aug;74(2):652-6
references: 6205021
references: Curr Opin Hematol. 2011 May;18(3):158-65
references: 21372708
references: Am J Hematol. 2010 Jun;85(6):403-8
references: 20513116
references: Blood. 1992 May 15;79(10):2555-65
references: 1375104
references: Blood. 2010 Jul 1;115(26):5300-11
references: 20223921
references: Blood. 1999 Sep 1;94(5):1550-4
references: 10477679
references: Lancet. 2011 May 14;377(9778):1663-72
references: 21571150
references: Am J Hematol. 2003 Dec;74(4):249-53
references: 14635205
references: J Pediatr Hematol Oncol. 1999 Sep-Oct;21(5):407-11
references: 10524455
references: N Engl J Med. 1995 May 18;332(20):1317-22
references: 7715639
references: Blood. 2010 Jun 3;115(22):4331-6
references: 20233970
references: Blood. 2011 Nov 3;118(18):4985-91
references: 21876119
references: Blood. 2010 Mar 25;115(12):2354-63
references: 19903897